NMS·Healthcare·$542M·#396 / 520 in Healthcare
PACB Pacific Biosciences of Californ
28HIGH RISK
CATEGORY BREAKDOWN
GROWTH6
QUALITY23
STABILITY10
VALUATION86
GOVERNANCE66
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+3.9%
6
> 50% strong
Gross Margin
Revenue retained after direct costs
28.6%
38
> 50% strong
Cash Runway
Months of cash at current burn rate
7 months
14
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
13131.8%
0
< 25% strong
Price / Sales
Market cap relative to trailing revenue
3.4x
86
< 3x strong
Rule of 40
Growth rate plus operating margin
-345
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
8.8%
59
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+3.4%
80
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE PACB WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when PACB's score changes by 5+ points.
DATA INFO
Last updated: Jul 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.